These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 19961912)

  • 1. Buspirone transdermal administration for menopausal syndromes, in vitro and in animal model studies.
    Shumilov M; Touitou E
    Int J Pharm; 2010 Mar; 387(1-2):26-33. PubMed ID: 19961912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and CNS pharmacodynamics of the 5-HT1A agonist buspirone in humans following acute L-tryptophan depletion challenge.
    Jagannathan V; Venitz J
    Methods Find Exp Clin Pharmacol; 1997 Jun; 19(5):351-62. PubMed ID: 9379784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic buspirone treatment normalizes open field behavior in olfactory bulbectomized rats: assessment with a quantitative autoradiographic evaluation of the 5-HT1A binding sites.
    Sato H; Skelin I; Debonnel G; Diksic M
    Brain Res Bull; 2008 Mar; 75(5):545-55. PubMed ID: 18355630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventive effect of oral estetrol in a menopausal hot flush model.
    Holinka CF; Brincat M; Coelingh Bennink HJ
    Climacteric; 2008; 11 Suppl 1():15-21. PubMed ID: 18464017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats.
    Haleem DJ; Samad N; Haleem MA
    Pharmacol Biochem Behav; 2007 May; 87(1):115-21. PubMed ID: 17498786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of steady state development and reduction of menopausal symptoms after oral or transdermal delivery of 17-β-estradiol in young healthy symptomatic menopausal women.
    Rohr UD; Volko CD; Schindler AE
    Horm Mol Biol Clin Investig; 2014 Jun; 18(3):123-36. PubMed ID: 25390008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buspirone induced acute and chronic changes of neural activation in the periaqueductal gray of rats.
    Lim LW; Temel Y; Sesia T; Vlamings R; Visser-Vandewalle V; Steinbusch HW; Blokland A
    Neuroscience; 2008 Jul; 155(1):164-73. PubMed ID: 18588948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic buspirone treatment normalizes regional serotonin synthesis in the olfactory bulbectomized rat brain: an autoradiographic study.
    Watanabe A; Hasegawa S; Nishi K; Nguyen KQ; Diksic M
    Brain Res Bull; 2006 Mar; 69(2):101-8. PubMed ID: 16533657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of soy isoflavones on menopausal neurovegetative symptoms.
    Colacurci N; Zarcone R; Borrelli A; De Franciscis P; Fortunato N; Cirillo M; Fornaro F
    Minerva Ginecol; 2004 Oct; 56(5):407-12. PubMed ID: 15531858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrinsic activity and comparative molecular dynamics of buspirone analogues at the 5-HT(1A) receptors.
    Strzelczyk AA; Jarończyk M; Chilmonczyk Z; Mazurek AP; Chojnacka-Wójcik E; Sylte I
    Biochem Pharmacol; 2004 Jun; 67(12):2219-30. PubMed ID: 15163553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral buspirone causes a shift in the dose-response curve between the elevated-plus maze and Vogel conflict tests in Long-Evans rats: relation of brain levels of buspirone and 1-PP to anxiolytic action.
    Vaidya AH; Rosenthal DI; Lang W; Crooke JJ; Benjamin D; Ilyin SE; Reitz AB
    Methods Find Exp Clin Pharmacol; 2005 May; 27(4):245-55. PubMed ID: 16082425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats.
    Zuideveld KP; Rusiç-Pavletiç J; Maas HJ; Peletier LA; Van der Graaf PH; Danhof M
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1130-7. PubMed ID: 12438536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and in vivo evaluation of an indapamide transdermal patch.
    Ren C; Fang L; Ling L; Wang Q; Liu S; Zhao L; He Z
    Int J Pharm; 2009 Mar; 370(1-2):129-35. PubMed ID: 19114099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of oral buspirone, pyridostigmine, and bethanechol on esophageal function evaluated with combined multichannel esophageal impedance-manometry in healthy volunteers.
    Blonski W; Vela MF; Freeman J; Sharma N; Castell DO
    J Clin Gastroenterol; 2009 Mar; 43(3):253-60. PubMed ID: 18987553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the 5HT1A receptor partial agonist buspirone on colorectal distension-induced pseudoaffective and behavioral responses in the female Wistar rat.
    Sivarao DV; Newberry K; Lodge NJ
    Eur J Pharmacol; 2004 Jun; 494(1):23-9. PubMed ID: 15194447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo evaluation of the transdermal iontophoretic delivery of sumatriptan succinate.
    Patel SR; Zhong H; Sharma A; Kalia YN
    Eur J Pharm Biopharm; 2007 May; 66(2):296-301. PubMed ID: 17182233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT.
    Serrano D; Mariani L; Mora S; Guerrieri-Gonzaga A; Cazzaniga M; Daldoss C; Ramazzotto F; Feroce I; Decensi A; Bonanni B
    Maturitas; 2006 Aug; 55(1):69-75. PubMed ID: 16500052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic absorption of amitriptyline and buspirone after oral and transdermal administration to healthy cats.
    Mealey KL; Peck KE; Bennett BS; Sellon RK; Swinney GR; Melzer K; Gokhale SA; Krone TM
    J Vet Intern Med; 2004; 18(1):43-6. PubMed ID: 14765730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.
    Eskow KL; Gupta V; Alam S; Park JY; Bishop C
    Pharmacol Biochem Behav; 2007; 87(3):306-14. PubMed ID: 17553556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zelrix: a novel transdermal formulation of sumatriptan.
    Pierce M; Marbury T; O'Neill C; Siegel S; Du W; Sebree T
    Headache; 2009 Jun; 49(6):817-25. PubMed ID: 19438727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.